Clinical Trials on Advanced B-cell Lymphoid Malignancies

Total 8414 results

Anand B. Karnad

Completed

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Advanced B-cell Lymphoid Malignancies

United States
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

China
Shanghai Escugen Biotechnology Co., Ltd
Escugen (Australia) Biotechnology Pty Ltd

Not yet recruiting

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
AstraZeneca

Active, not recruiting

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

Part1: Advanced B-cell Malignancies | Part2: r/rCLL and r/rMCL | Part3: Untreated CLL

Japan
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
AbbVie
Genentech, Inc.

Active, not recruiting

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Non-Hodgkin's Lymphoma | Hematological Malignancies | Chronic Lymphoid Leukemia | CD20-Positive Lymphoid Malignancies

United States, Australia
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Peripheral T-cell Lymphoma | Lymphoid Malignancies | Chronic Lymphoid Leukemia

United States, Canada
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Leukemia

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | B-Cell Non-Hodgkin Lymphomas(NHL)

China
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
Gilead Sciences

Terminated

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's Lymphoma

United States, Canada
AbbVie

Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | B Cell Malignancies

United States, Israel, Australia, France, United Kingdom, Belgium, Spain
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Baptist Health South Florida

Withdrawn

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Non-Hodgkin Lymphoma | Hematologic Malignancy | B-Cell Lymphoid Malignancies

United States
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Xuzhou Medical University

Recruiting

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Unknown

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

Advanced Solid Tumors | Lymphoid Malignancies

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Astellas Pharma Inc

Completed

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Solid Tumor | B-Cell Lymphoma | Advanced Malignancies | Positive for Anaplastic Lymphoma Kinase | Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS

United States
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Innovative Cellular Therapeutics Co., Ltd.

Unknown

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Lymphoma, B-Cell | Leukemia, B-Cell

China
M.D. Anderson Cancer Center

Completed

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | B-Lymphoid Malignancies | Non-hodgkin Lymphoma

United States
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
Sunesis Pharmaceuticals

Completed

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | B-lymphoid Malignancies

United States
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

Australia, China
Athenex, Inc.

Recruiting

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2)

B-cell Lymphoma | CLL/SLL | ALL, Childhood | DLBCL - Diffuse Large B Cell Lymphoma | B-cell Leukemia | NHL, Relapsed, Adult | ALL, Adult B Cell

United States
University of Alabama at Birmingham

Terminated

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin's Lymphoma | CLL / SLL | Waldenstroms

United States
Amgen

Completed

AMG 319 Lymphoid Malignancy FIH

Lymphoma | Leukemia | Cancer | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Hematologic Malignancies | Diffuse Large Cell Lymphoma | Oncology | Tumors | T Cell Lymphoma | Oncology Patients | Hematology | Low Grade Lymphoma

United States
University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
University of Milano Bicocca

Recruiting

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

Mantle-cell Lymphoma | B Cell Chronic Lymphocytic Leukemia

Italy
Roswell Park Cancer Institute

Not yet recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide (CLL1818)

Chronic Lymphoid Leukemia | Large-B-cell Diffuse Lymphoma

Italy
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Multiple Myeloma | Waldenstrom's Macroglobulinemia | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B-cell Lymphoma | B-Cell Chronic Lymphocytic Leukemia | Enteropathy Associated T-cell Lymphoma | B-cell Follicular Lymphoma | B-cell Marginal Zone Lymphoma | B-cell Mantle... and other conditions

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Advanced Solid Tumors | Advanced B-cell NHL

United States, France, Spain, Germany
iOMEDICO AG

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (RUBIN)

Chronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)

Germany
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma

United States
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
AstraZeneca

Active, not recruiting

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Phase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

China
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Follicular Lymphoma | B Cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Small Lymphocytic Leukemia

Korea, Republic of, United States
TransThera Sciences (Nanjing), Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

B-Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China

Clinical Trials on Advanced B-cell Lymphoid Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations